-
Mashup Score: 0DDR Mutations Not Linked to Clinical Benefit of Olaparib in mUC - 8 month(s) ago
Poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors may offer a therapeutic benefit in patients with metastatic urothelial cancer (mUC). PARP inhibitors are the first approved targeted agent to manage DNA damage response (DDR) genes and have demonstrated a clinical benefit in patients with solid tumors who carry germline or somatic alt erations in those genes. As somatic alterations in DDR genes are common in patients with advanced urothelial cancer, researchers examined the use of the PARP
Source: guoncologynow.comCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0DDR Mutations Not Linked to Clinical Benefit of Olaparib in mUC - 8 month(s) ago
Poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors may offer a therapeutic benefit in patients with metastatic urothelial cancer (mUC). PARP inhibitors are the first approved targeted agent to manage DNA damage response (DDR) genes and have demonstrated a clinical benefit in patients with solid tumors who carry germline or somatic alterations in those genes. As somatic alterations in DDR genes are common in patients with advanced urothelial cancer, researchers examined the use of the PARP
Source: guoncologynow.comCategories: Latest Headlines, Partners & KOLsTweet-
Researchers examined the use of the PARP inhibitor #olaparib to determine the drug’s potential therapeutic benefit in patients with metastatic #urothelialcarcinoma with somatic DDR alterations: https://t.co/AERD3wrF5t https://t.co/BfHvgt1iNm
-
-
Mashup Score: 0
In an interview with Targeted Oncology, Yago Nieto, MD, PhD, discussed the implications of findings from the phase 1 study assessing olaparib and high-dose chemotherapy in patients with relapsed/refractory lymphomas.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Yago Nieto, MD, PhD, discussed a phase 1 study of #olaparib and high-dose chemotherapy in patients with relapsed/refractory lymphomas. #lymsm | @MDAndersonNews https://t.co/SwKPiy6dWd https://t.co/yp2KZB7V5F
-
-
Mashup Score: 0Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors - 9 month(s) ago
AbstractBackground. Poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment of ovarian cancer; however, real-world data on kidney func
Source: academic.oup.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
This study in @JNCI_Now investigates the incidence of acute kidney injury (AKI) in #ovariancancer patients treated with #olaparib or #niraparib. They found 22.3% developed AKI but only 3.3% had AKI related to the #PARP inhibitor. #gyncsm Read more: https://t.co/qiRAfsMxDK https://t.co/2iYEn8jvVP
-
-
Mashup Score: 2Impact of BRCA1 and RAD15 Methylation on Maintenance Olaparib Plus Bevacizumab Efficacy in Ovarian Cancer - 9 month(s) ago
At the 2023 ASCO Annual Meeting, Helene Blons, PhD, PharmD, discusses results from an abstract addressing the impact of BRCA1 and RAD51 methylation on the efficacy of olaparib plus bevacizumab maintenance treatment, from the PAOLA-1/ENGOT-ov25 trial.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At the 2023 @ASCO annual meeting, Helene Blons, PhD, PharmD, discussed results from the PAOLA-1/ENGOT-ov25 trial. Learn more here: https://t.co/EVbv6Q0JeW #medtwitter #onctwitter #olaparib #bevacizumab #ASCO23 https://t.co/pAXt4PgrzW
-
-
Mashup Score: 0Nouvelles AMM : olaparib en combinaison à l’abiratérone dans le cancer de la prostate métastatique résistant à la castration - 9 month(s) ago
Author links open overlay panel Annabelle Sabouret 1, Philippe Beuzeboc 2 Le cancer de la prostate est un des cancers les plus fréquents, représentant le deuxième cancer le plus fréquent chez l’homme dans le monde, et se plaçant au premier rang en termes d’incidence en France. La survie à cinq ans est de 90 %, et la mortalité est actuellement en diminution, du fait de A.Sabouret ne déclare pas de liens d’intér êt. P.Beuzeboc déclare avoir des liens d’intérêts avec Janssen, Astellas, Ipsen, Bayer, Astra
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet-
Nouvelles AMM : #olaparib in combination with #adibaterone in #ProstaticCancer #pubmed https://t.co/VEPLhENN4g
-
-
Mashup Score: 0Sign up - 11 month(s) ago
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Looking forward to #ASCO23 presentation by @SandhuShahneen @PeterMacCC - #LuPARP: Phase 1 trial of 177Lu-PSMA-617 and #olaparib in patients w/ metastatic castration-resistant #ProstateCancer #mCRPC. Don't miss written coverage following on UroToday! https://t.co/JohbdZbjLm @ASCO https://t.co/L3MOApCOwM
-
-
Mashup Score: 3FDA Approves Olaparib Triplet for mCRPC - 11 month(s) ago
Findings from the phase 3 PROpel have led to the FDA approval of olaparib in combination with abiraterone and prednisone or prednisolone for a prostate cancer subgroup.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
BREAKING: The #FDA has approved #olaparib in combination with #abiraterone and #prednisone or #prednisolone for adult patients with #mCRPC. #pcsm | @DukeCancer @FDAOncology https://t.co/1Yc2JZjrER https://t.co/W7r5Qs1bKr
-
-
Mashup Score: 0
The Oncologic Drugs Advisory Committee has discussed the approval application for olaparib plus abiraterone and prednisone or prednisolone for patients with metastatic castration-resistant prostate cancer and voted on its potential future.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: The FDA’s ODAC voted 11 to 1 in favor of restricting the sNDA for #olaparib with abiraterone and prednisone or prednisolone for metastatic castration-resistant prostate cancer to patients with BRCA-mutant tumors only. #pcsm #mCRPC https://t.co/nnSFzggT7u
-
-
Mashup Score: 3Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Therapy with PARP inhibitor #olaparib provided sustained benefit beyond the end of initial treatment for patients with newly diagnosed advanced #ovarian cancers expressing the BRCA mutation. @OvarianCancerDY https://t.co/u2HfrI18cp https://t.co/bG4OebPOAo
-
Researchers examined the use of the PARP inhibitor #olaparib to determine the drug’s potential therapeutic benefit in patients with metastatic #urothelialcarcinoma with somatic DDR alterations: https://t.co/AERD3wrF5t https://t.co/usu33WiXzf